Atezolizumab
Tecentriq · Anti-PD-L1 antibody
Interstitial nephritis; rare glomerular disease.
Iressa · GEF
EGFR TKI · approved 2003 · 12 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
An EGFR TKI implicated in rare nephrotic syndrome (minimal-change and membranous patterns) and occasional AKI.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Nephrotic syndrome (minimal-change disease and secondary membranous nephropathy patterns) and rare acute renal failure are reported only as isolated cases; not quantified in clinical-trial datasets.Source: Maruyama et al., Intern Med 2015
Weeks to months after initiation; proteinuria resolves over weeks to months after stopping.
Distilled from: “Weeks to months after initiation in reported cases; proteinuria resolves over weeks to months after stopping the drug.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Damage to the filtration barrier — podocyte injury, FSGS and protein leak from VEGF and mTOR blockade.
Immune-mediated inflammation of the renal interstitium — the signature kidney injury of checkpoint inhibitors.
Case reports plus a prospective series attribute hemorrhagic cystitis to gefitinib, improving on discontinuation.
Tap a signature to trace where it strikes the nephron.
Glomerular Injury / Proteinuria strikes: Glomerulus.
Glomerular Injury / Proteinuria
Damage to the filtration barrier — podocyte injury, FSGS and protein leak from VEGF and mTOR blockade.
Selective, reversible EGFR tyrosine kinase inhibitor that blocks EGFR autophosphorylation and downstream signaling driving tumor proliferation. Used for EGFR-mutant non-small cell lung cancer.
Class-level context for the major non-renal toxicities of the EGFR TKI class.
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
Pulmonary
Pneumonitis, ILD, effusions, hypertension
10 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Quoted verbatim from this agent's current FDA label (Mar 2026) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
Less than four percent (<4%) of gefitinib and its metabolites are excreted via the kidney. No clinical studies were conducted with gefitinib tablets in patients with severe renal impairment.
Kidney rows of the label's dosage tables
None of the newest openFDA labels for this product carries a dosage table. The label's prose can still give kidney instructions.
Everything below is FAERS — adverse events someone chose to report, about 8,990 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
1,954 of 8,990 reports
Reported with hospitalization
2,580 of 8,990 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 3,883 of the 8,990 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Gefitinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Tecentriq · Anti-PD-L1 antibody
Interstitial nephritis; rare glomerular disease.
Blenrep · Antibody-drug conjugate (BCMA/MMAF)
Myeloma ADC; renal data emerging.
Bavencio · Anti-PD-L1 antibody
ICI-associated AIN.
Libtayo · Anti-PD-1 antibody
ICI-associated AIN.
Jemperli · Anti-PD-1 antibody
ICI-associated AIN.
Imfinzi · Anti-PD-L1 antibody
ICI-associated AIN.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Gefitinib’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Gefitinib; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 31 clinical records among all 53 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.